ZIZeynep Erdogan Iyigun

Zeynep Erdogan Iyigun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zeynep Erdogan Iyigun has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Long-Term Lymphedema Rate in Patients With Subclinical Lymphedema Diagnosed in the Preoperative Period via Bioimpedance

    by Zeynep Erdoğan İyigün, Tolga Ozmen, Serkan İlGün, Cansu Nakipoğlu, Enver Özkurt, Filiz Çelebi, Çağlar Ünal, Alper Öztürk, Gül Alço, Çetin Ordu, et al.

    Undefined - European Journal of Breast Health


  • The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer

    by Ahmet Serkan Ilgun, Fatma Aktepe, Onur Gonullu, Nilgun Kapucuoglu, Kanay Yararbas, Gul Alco, Alper Ozturk, Filiz Elbuken Celebi, Zeynep Erdogan, Cetin Ordu, et al.

    Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: One hundred fifteen pa... Plain language summary New studies have shown that the tumor microenvironment is critical in tumor behavior. Immune cells surrounding tumor cells are the main components of the tumor microenvironme...


  • The Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trial

    by Filiz Celebi, Cetin Ordu, Ahmet Serkan Ilgun, Alper Ozturk, Zeynep Erdogan Iyigun, Gul Alco, Tomris Duymaz, Fatma Aktepe, Gursel Soybir, Bulent Baysal, et al.

    AMH,ovarian reserve,breast cancer,chemotherapy


  • Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes

    by Cetin Ordu, Kezban Nur Pilanci, Gul Alco, Filiz Elbuken, Ulkuhan Iner Koksal, Serkan Ilgun, Dauren Sarsenov, Ayse Esra Aydin, Alper Ozturk, Zeynep İyIgun Erdogan, et al.

    Objective: In this retrospective study, chemotherapy induced amenorrhea in patients with early stage breast cancer and its effects on survival were investigated. Materials and Methods: Two hundred fifty-two patients received adjuvant chemotherapy without ovarian suppression treatment (OST) from 600 premenopausal patients were included in the study. Patients were divided into two groups; with amenorrhea and without, and compared with clinicopathologic features and survival. SPSS version 17 was used. Results: Chemotherapy-induced amenorrhea (CIA) was observed in 145 (57.5%) of 252 patients who received no OST during follow-up. The 5-year OS rate of patients with CIA was significantly higher than patients without CIA (p=0.042, 95.9% vs. 89.7% vs. 158.88 vs. 135.33 months, respectively). In the subgroup analysis, the OS in patients with hormone receptor (+) was significantly higher than in those receptor (-) in patients with CIA (p=0.011, 97.5% vs. 90.9% vs. 162.13 vs. 126.16 months, respectively). The OS was significantly longer in the luminal A molecular subtype than in those with luminal B molecular subtype, in patients with CIA, but the difference was not significant in patients without CIA (p=0.027 vs. p=0.074, respectively).** Conclusion: As a conclusion; survival advantage of the chemotherapy induced amenorrhea more pronounced with hormone receptor positivity, lymph node involvement, and advanced disease over patients who do not develop amenorrhea. This advantage of amenorrhea development further prolongs survival compared with luminal B in the luminal A molecular subtype.


  • Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer

    by Zeynep Erdogan Iyigun, Tomris Duymaz, Ahmet Serkan Ilgun, Gul Alco, Cetin Ordu, Dauren Sarsenov, Ayse Esra Aydin, Filiz Elbuken Celebi, Filiz Izci, Yeşim Eralp, et al.

    Background: Prolongation of survival in patients with breast cancer due to early diagnosis and modern methods of treatment has turned the attention on lymphedema, which is the most important morbidity secondary to the treatment of the disease. Determination of lymphedema and related risk factors in patients before a surgical intervention may provide protection for patients and early treatment. The aim of this study was to determine the presence of lymphedema before surgery by bioimpedance analysis in patients with breast cancer and to establish risk factors associated with lymphedema. Patients and Methods: A total of 277 patients who were diagnosed as having breast cancer, were planned to undergo a surgical intervention, and had no clinical lymphedema were included in the study. The presence of lymphedema was evaluated with clinical examination, measurement of arm circumference, and bioimpedance analysis. Results: Lymphedema was found in 59 (21.3%) patients with no detected differences in arm circumferences. A significant relationship was found between the presence of lymphedema and body mass index (BMI), number of positive lymph nodes, and capsule invasion of the tumor (p = 0.001, p = 0.003, p = 0.002, respectively). Multiple regression analysis revealed that BMI and the number of positive lymph nodes were independent variables (p = 0.024, p = 0.002). ROC curve analysis resulted in an increased risk of preoperative lymphedema when the number of positive lymph nodes was ≥8. Correlation analysis revealed a positive correlation between the number of positive lymph nodes and L-dex score (p = 0.001, r = 0.219). Conclusion: Preoperative bioimpedance analysis demonstrated that ∼1/5 of the patients had subclinical lymphedema. Preoperative subclinical lymphedema is associated with obesity and the number of positive lymph nodes, and thus, treatment of the axilla in patients who are preoperatively detected to have subclinical lymphedema should be revised.